Bernstein Downgrades Salesforce Amid Agentforce Momentum Concerns
By EC Assets · Published
Bernstein has downgraded its rating on Salesforce, citing a lack of evidence for momentum in the company's Agentforce product. The downgrade was revealed in a note on Thursday. This follows a previous downgrade by KeyBanc, which expressed doubts regarding Salesforce's AI narrative. One analysis suggests Salesforce shares may appear to be a bargain, but this perception could be a mirage. Agentforce is recognized as Salesforce's autonomous AI agent platform. It is designed to handle customer interactions, sales workflows, and operational tasks without human intervention. Salesforce has committed a $1 billion investment to Agentforce. Agentforce Sales for Slack integrates AI, people, and CRM data into a unified workspace. This allows users to prospect, manage pipelines, and close deals within their existing tools. Agentforce Sales operates behind the scenes, automatically advancing deals and suggesting appropriate next actions. Salesforce plans to launch Agentforce Help Agent, an autonomous service agent built on the Agentforce 360 Platform, which is deployable in minutes. The platform is described as an umbrella term for tools that create and customize agents, as well as a collection of agents provided by Salesforce across various customer functions. Agentforce integrates with Salesforce reporting, making metrics visible in real time and enabling continuous optimization of customer success workflows. There is an enablement path for individual consultants at partner firms who design and deliver Agentforce solutions, known as FDE Ready. SalesforceFAQs channel has discussed Agentforce, focusing on building AI agents in Salesforce through live demonstrations. Salesforce Developer Advocates Mohith Shrivastava and Sean Keegan have also created a fully functional AI, powered React app on Salesforce in a live coding session. This article is intended for informational purposes only. It does not constitute investment advice.
Stay informed
Market commentary, firm news and research from EC Assets - direct to your inbox.